دورية أكاديمية
Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers
العنوان: | Improved efficiency of daratumumab treatment of multiple myeloma adopting the subcutaneous route: A micro‐costing analysis in three Italian hematology centers |
---|---|
المؤلفون: | Lorenzo Pradelli, Massimo Massaia, Elisabetta Todisco, Filippo Gherlinzoni, Anna Furlan, Maria La Targia, Elisabetta Grande, Ignazio Ezio Tripoli, Francesca Occhipinti, Francesco Comello, Fabrizio Iannello, Stefania Bellucci |
المصدر: | Cancer Medicine, Vol 12, Iss 23, Pp 21480-21489 (2023) |
بيانات النشر: | Wiley, 2023. |
سنة النشر: | 2023 |
المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
مصطلحات موضوعية: | cancer management, clinical management, clinical observations, drug discovery and delivery, multiple myeloma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
الوصف: | AbstractBackgroundDaratumumab is a humanized monoclonal antibody approved for the treatment of adult patients with newly diagnosed or relapsed/refractory multiple myeloma (RRMM). Subcutaneous (SC) formulation proved to be non‐inferior in comparison with intravenous (IV) administration route. This study aimed at assessing the economic and time impact associated with the use of SC versus IV daratumumab in patients with RRMM from the perspective of the hematology center.MethodsThis was a 5‐month multicenter time‐and‐motion cross‐sectional micro‐costing study conducted in three Italian hematology centers among adult patients diagnosed with RRMM with ongoing treatment with IV or SC daratumumab. Measurements were performed by an ad hoc App. ResultsNineteen (20%) IV and 76 (80%) SC administration procedures were measured. Patients spent a mean of 4.85 ± 0.91 or 1.08 ± 0.56 h in the hematology center to receive IV or SC daratumumab, respectively. Healthcare professionals (HCPs) spent a mean of 49.38 ± 16.13 and 20.37 ± 7.88 min of active working time to manage IV and SC administrations, respectively. The infusion chair was occupied for a mean of 4.85 ± 0.91 and 0.99 ± 0.55 h during IV or SC administration, respectively. On average, considering the costs due to HCP and chair time, materials, and overhead costs, every IV and SC administration costed €80.33 and 34.90, respectively. ConclusionsIn conclusion, as compared with IV administration, SC daratumumab was associated with 78%, 59%, 80% savings in terms of patient time, HCP active working time, and infusion chair, respectively, and 56.6% budget savings. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 2045-7634 |
Relation: | https://doaj.org/toc/2045-7634 |
DOI: | 10.1002/cam4.6699 |
URL الوصول: | https://doaj.org/article/5dcf619164e4483fa8e61f35f99b0399 |
رقم الأكسشن: | edsdoj.5dcf619164e4483fa8e61f35f99b0399 |
قاعدة البيانات: | Directory of Open Access Journals |
كن أول من يترك تعليقا!